Pharmamar SA, of Madrid, said Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson, submitted a new drug application (NDA) seeking FDA approval of Yondelis (trabectedin) for use in soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes who have received prior chemotherapy, including an anthracycline.